Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PCX-12.
- Who it may be relevant to
- Registry conditions: Pancreatic Adenocarcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase 1, Prospective, Standard Dose Escalation Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)
Overview
The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.
Detailed description
Single center, open label, escalating dosage of PCX12 with standard of care practice for subjects who are diagnosed with adenocarcinoma of the head of the pancreas. Subjects with undergo standard of care radiation therapy and then start on PCX12 therapy starting at 200 ng/kg of PCX12 escalating to a potential maximum dosage of 800 ng/kg of PCX12 with adjacent tolerability and safety guidelines.
Interventions
- Drug PCX-12
treatment combining radiation therapy with PCX12
Primary outcome measures
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [Time frame: 3 years]
- Maximum tolerable dose [Safety and Tolerability] [Time frame: 3 years]
Secondary outcome measures (2)
- Rate of radiographic response [Time frame: 2 months]
- Change in biomarkers of innate and adaptive immunity [Time frame: baseline and 4 weeks]
Eligibility criteria
Inclusion criteria
- Patient with pathologically proven diagnosis of adenocarcinoma of the pancreas
- After chemotherapy, tumor is determined to be either locally advanced or unresectable by hepatobiliary surgeon; or tumor is considered potentially resectable but subject does not proceed with surgical resection for any reason
- Have completed first line chemotherapy without progression or non-regional metastases
- Tumor is radiographically evident on CT scan after chemotherapy
- Tumor is anatomically amenable to SBRT, e.g. does not directly invade the stomach or bowel
- Tumor is amenable to intra-tumor injection under endoscopic ultrasound guidance
- ECOG performance status 0-2
- Patients with childbearing potential must demonstrate a negative urine or serum pregnancy test
- Male or female subjects, aged at least 18 years; Female subjects of childbearing potential may participate if adequate contraception is used during, and for at least the three months after study completion; Male subjects with partners of childbearing potential may participate in the study if they had a vasectomy at least 6 months prior to randomization or if adequate contraception is used during, and for at least the three months after study completion; Adequate contraception is defined as resulting in a failure rate of less than 1% per year
- Patient must be able to understand and willingly sign study specific informed consent prior to study entry
- Anticipated life expectancy ≥ 12 weeks
- Patients aged at least 18 years of age
Exclusion criteria
- Progression of disease or metastatic disease after first line systemic therapy
- Prior radiation treatment or surgical resection of any pancreatic malignancy
- Inability to tolerate SBRT, Endoscopic ultrasound or IL-12 Injection procedure
- Lack of radiographically evident disease after first line chemotherapy
- Severe, active comorbidity that shortens the patient's life expectancy to less than 12 weeks
- History of past malignancy
- Patient who is pregnant and/or breastfeeding
- Inability to comply with other required protocol procedures including required biopsies
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of Rochester — Rochester
Identifiers
NCT: NCT06217666 · URGIP24061